Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aqilion","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$1,025.0 million","upfrontCash":"$10.6 million","newsHeadline":"Aqilion Announces Pre-Clinical Licensing and Strategic Research Collaboration Agreement with Merck","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Aqilion

    Menu

    Aqilion

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aqilion

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aqilion Announces Pre-Clinical Licensing and Strategic Research Collaboration Agreement with Merck

              Details:

              Under the terms of the collaboration, Aqilion will be responsible for the design and synthesis of novel small molecule TAK1 inhibitors while Merck will lead preclinical pharmacology and biology studies.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck Group

              Deal Size: $1,025.0 million Upfront Cash: $10.6 million

              Deal Type: Collaboration February 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY